Barbara Rosado Carrion, MD
Gastroenterology · Ponce, PRNPI 1467448191
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,411 of the $175,743 with a category attached, or 90.1%. 16 manufacturers reported payments, led by AbbVie at 49.9% of the total. 2025 is the largest year on record at $48,829, 2.3 times the $21,300 reported in 2019. Among gastroenterology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $744.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$88K
- Madrigal Pharmaceuticals$43K
- Gilead$42K
- Merck$1K
- E.r. Squibb & Sons, L.L.C.$595
- Intercept Pharmaceuticals, Inc.$197
- plus $748 from 10 others
Across 30 payments — averaging $960.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$21K
- Intercept Pharmaceuticals, Inc.$6K
- Eli Lilly Export S.A. Puerto Rico Branch$814
- Eli Lilly$659
What the payments were for
- Consulting fees$2,5001%
- Speaking & faculty fees$158,41190%
- Travel & lodging$8,3865%
- Food & beverage$6,3404%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $87,718 |
| Madrigal Pharmaceuticals | 25 | $42,840 |
| Gilead | 65 | $42,433 |
| Merck | 2 | $1,212 |
| E.r. Squibb & Sons, L.L.C. | 21 | $595 |
| Intercept Pharmaceuticals, Inc. | 5 | $197 |
| Ipsen Biopharmaceuticals, Inc | 2 | $149 |
| Olympus Latin America, Inc. | 1 | $147 |
| PBG Puerto Rico LLC | 6 | $124 |
| Pfizer Pharmaceuticals LLC | 2 | $106 |
| Johnson & Johnson | 1 | $99 |
| GSK | 1 | $51 |
| Orphalan Inc | 1 | $28 |
| Eisai Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Pfizer | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$175,743 in reported general payments places this provider in the 95th percentile of 198 gastroenterology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 13 | $317,031 |
| XifaxanRifaximin | 36 | $116,229 |
| ZeposiaOzanimod Hydrochloride | 11 | $95,833 |
| Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir | 12 | $88,720 |
| Humira(Cf) PenAdalimumab | 13 | $87,472 |
| RezdiffraResmetirom | 12 | $47,684 |
| VemlidyTenofovir Alafenamide | 21 | $42,610 |
| PrografTacrolimus | 78 | $41,584 |
| LinzessLinaclotide | 51 | $29,843 |
| Dexlansoprazole DrDexlansoprazole | 118 | $29,195 |
| Sucralfate | 124 | $17,682 |
| Ursodiol | 175 | $17,410 |
| DexilantDexlansoprazole | 48 | $15,073 |
| SuprepSodium, Potassium,mag Sulfates | 117 | $13,821 |
| MotegrityPrucalopride Succinate | 20 | $10,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $42,433 | $359,64134 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $16 | $116,22936 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $595 | $95,83311 claims |
| Madrigal PharmaceuticalsRezdiffra | $42,840 | $47,68412 claims |
| AbbVieLinzess | $87,718 | $29,84351 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 198 gastroenterology providers in Puerto Rico.
Other gastroenterology in Ponce
- Ahmed Morales JorgeCoto Laurel$214K
- Rafael Pastrana LabordeHato Rey$76K
- Miguel de Varona-NegronCaguas$68K
- Marcia Cruz CorreaSan Juan$62K
- Francisco CebolleroMayaguez$52K
- Loscar SantiagoSan Juan$39K
- Henry Gonzalez RiveraSan Juan$34K
- Hector LozanoSan Juan$28K
- Carlos MicamesMayaguez$22K
- Rafael Rodriguez LopezSan Juan$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.